Login / Signup

Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al.

Alessandra BettiolFrancesca PregnolatoSavinio SciasciaPier Luigi MeroniDomenico Prisco
Published in: Annals of the rheumatic diseases (2020)
Keyphrases
  • systemic lupus erythematosus
  • double blind
  • placebo controlled
  • clinical trial
  • study protocol
  • open label
  • squamous cell carcinoma
  • combination therapy
  • phase ii
  • replacement therapy